HK1043537A1 - 通過tie2受體激活劑調節血管通透性 - Google Patents

通過tie2受體激活劑調節血管通透性

Info

Publication number
HK1043537A1
HK1043537A1 HK02103669.2A HK02103669A HK1043537A1 HK 1043537 A1 HK1043537 A1 HK 1043537A1 HK 02103669 A HK02103669 A HK 02103669A HK 1043537 A1 HK1043537 A1 HK 1043537A1
Authority
HK
Hong Kong
Prior art keywords
vascular permeability
modulation
mean
tie2 receptor
receptor activators
Prior art date
Application number
HK02103669.2A
Other languages
English (en)
Inventor
Suri Chitra
D Yancopoulos George
Thurston Gavin
Mcdonald Donald
Original Assignee
Regeneron Pharma
Univ Of California San Francisco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by Regeneron Pharma, Univ Of California San Francisco filed Critical Regeneron Pharma
Publication of HK1043537A1 publication Critical patent/HK1043537A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02103669.2A 1999-03-26 2002-05-15 通過tie2受體激活劑調節血管通透性 HK1043537A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (1)

Publication Number Publication Date
HK1043537A1 true HK1043537A1 (zh) 2002-09-20

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103669.2A HK1043537A1 (zh) 1999-03-26 2002-05-15 通過tie2受體激活劑調節血管通透性

Country Status (14)

Country Link
EP (1) EP1165115B1 (zh)
JP (1) JP2002540165A (zh)
AT (1) ATE241380T1 (zh)
AU (1) AU769198B2 (zh)
CA (1) CA2368670C (zh)
DE (1) DE60003011T2 (zh)
DK (1) DK1165115T3 (zh)
ES (1) ES2199804T3 (zh)
HK (1) HK1043537A1 (zh)
IL (2) IL145504A0 (zh)
NO (1) NO329198B1 (zh)
NZ (1) NZ514434A (zh)
PT (1) PT1165115E (zh)
WO (1) WO2000057901A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
ES2411505T3 (es) * 2005-12-15 2013-07-05 Medimmune Limited Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009097325A1 (en) 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
SG172312A1 (en) * 2009-01-12 2011-07-28 Akebia Therapeutics Inc Methods for treating vascular leak syndrome
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2832746B1 (en) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
BR112018005499A2 (pt) 2015-09-23 2018-10-09 Aerpio Therapeutics Inc métodos de tratamento de pressão intraocular com ativadores de tie-2.
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE-2 ACTIVATORS TARGETING THE SCHLEMM CHANNEL

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
EP0956339B1 (en) * 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08
IL145504A0 (en) 2002-06-30
JP2002540165A (ja) 2002-11-26
DK1165115T3 (da) 2003-09-22
ES2199804T3 (es) 2004-03-01
AU769198B2 (en) 2004-01-22
NO20014673D0 (no) 2001-09-26
NO329198B1 (no) 2010-09-13
PT1165115E (pt) 2003-10-31
AU3763400A (en) 2000-10-16
EP1165115A1 (en) 2002-01-02
ATE241380T1 (de) 2003-06-15
DE60003011D1 (de) 2003-07-03
IL145504A (en) 2008-08-07
NO20014673L (no) 2001-11-22
EP1165115B1 (en) 2003-05-28
WO2000057901A1 (en) 2000-10-05
NZ514434A (en) 2003-11-28
CA2368670A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
HK1043537A1 (zh) 通過tie2受體激活劑調節血管通透性
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
IL147803A0 (en) 28-epirapalogs
MXPA03002477A (es) N-acilsulfonamidas promotras de la apoptosis.
SI1187632T1 (sl) Zdravljenje z anti-ErbB2 protitelesi
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
PL328858A1 (en) Immunogenous peptides
MY127495A (en) Dipeptide derivatives
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
HK1032746A1 (en) Bridged indenopyrrolocarbazoles.
EP0462661A3 (en) Novel 17beta-hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones as testosterone reductase inhibitors
GB2358397A (en) Method of preparing delta-9-tetrahydrocannabinol esters
AP2001002274A0 (en) Rescorcinol derivatives.
MY124078A (en) Eletriptan hydrobromide monohydrate
DE60022095D1 (en) Camptothecin-beta-alanin-ester mit topoisomerase i hemmung
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner
MXPA02002315A (es) Metodos y composiciones para reducir los niveles de fosfato en suero.
AU3219700A (en) Method for the preparation of a chiral-beta-amino ester
MXPA02004021A (es) Mezcla terapeutica de inhibidores de hmg-coa reductasa.
AU5203600A (en) H-bn modified p/m stainless steels
AU9294698A (en) Methods and compositions for enhanced wound healing
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
GB0128052D0 (en) Compounds
EP1162886A4 (en) SYSTEM AND METHOD FOR EVALUATING OXIDATIVE DESTRUCTIVE AGENTS